|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2005; 46:1258-1263, doi:10.1016/j.jacc.2005.06.058 © 2005 by the American College of Cardiology Foundation |
* Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland
Department of Epidemiology and Public Health, Royal College of Surgeons in Ireland, Dublin, Ireland
Department of Cardiology, Beaumont Hospital, Dublin, Ireland
Department of Cardiology, St. James’s Hospital, Dublin, Ireland
Manuscript received February 11, 2005; revised manuscript received June 7, 2005, accepted June 13, 2005.
* Reprint requests and correspondence: Dr. Dermot Cox, Department of Clinical Pharmacology, The Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland. (Email: dcox{at}rcsi.ie).
OBJECTIVES: We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals.
BACKGROUND: Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease; however, there is variability in the way individuals respond. Persistent normal platelet function despite therapy, referred to as "aspirin resistance," is associated with an increased risk of major cardiovascular events.
METHODS: We studied 131 stable cardiovascular patients between March and September 2002 who were taking 75 mg EC aspirin. Serum thromboxane (TX) B2 levels were assayed as a measure of COX activity. Mean arachidonic acid (AA)-induced platelet aggregation 
20% was deemed evidence of persistent platelet activity and an incomplete aspirin response.
RESULTS: Patients of median age 63 years (61% men) were enrolled. Forty-four percent of patients had elevated serum TX B2 levels (>2.2 ng/ml). Arachidonic acid-induced platelet aggregation occurred more frequently in these patients (21% vs. 3%; p = 0.004). In all cases addition of exogenous aspirin during the assay abolished platelet aggregation. Patient weight and age were significant independent predictors of an incomplete response to EC aspirin (p = 0.025 and p < 0.001, respectively). These patients were also more likely to have a history of myocardial infarction (MI) (p = 0.038).
CONCLUSIONS: Many patients who are prescribed low-dose EC aspirin for secondary prevention of cardiovascular events have persistent uninhibited platelet COX activity. Younger and heavier patients and those with a previous MI are most likely to have an inadequate response to treatment.
| ||||||||
This article has been cited by other articles:
|
|
 |
|
  S. Prabhakaran, K.R Wells, V.H. Lee, C.A. Flaherty, and D.K. Lopes Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 281 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Capone, S. Tacconelli, M. G. Sciulli, P. Anzellotti, L. Di Francesco, G. Merciaro, P. Di Gregorio, and P. Patrignani Human Pharmacology of Naproxen Sodium J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D. A. Palisaitis, and J. G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur. Heart J., July 2, 2007; 28(14): 1702 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Fitzgerald and A. Maree Aspirin and Clopidogrel Resistance Hematology, January 1, 2007; 2007(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Maree, H. Jneid, and D. J. Fitzgerald Aspirin Resistance and Atherothrombotic Disease J. Am. Coll. Cardiol., August 15, 2006; 48(4): 846 - 847. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cox, A. O. Maree, M. Dooley, R. Conroy, M. F. Byrne, and D. J. Fitzgerald Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers Stroke, August 1, 2006; 37(8): 2153 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Freedman The Aspirin Resistance Controversy: Clinical Entity or Platelet Heterogeneity? Circulation, June 27, 2006; 113(25): 2865 - 2867. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Evangelista, S. Manarini, A. Di Santo, M. L. Capone, E. Ricciotti, L. Di Francesco, S. Tacconelli, A. Sacchetti, S. D'Angelo, A. Scilimati, et al. De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin Circ. Res., March 17, 2006; 98(5): 593 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Wang, D. L. Bhatt, and E. J. Topol Aspirin and clopidogrel resistance: an emerging clinical entity Eur. Heart J., March 2, 2006; 27(6): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Is Low-Dose Enteric-Coated Aspirin Sufficient in Stable CAD? Journal Watch Cardiology, November 4, 2005; 2005(1104): 2 - 2. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
